In vitro studies present that lnc‐ITSN1‐2 activates CD4+ T cell, then stimulates Th1 and Th17 cell differentiation through targeting microRNA 125a (miR‐125a) in inflammatory bowel disease (IBD)18; suppressing lnc‐ITSN1‐2 could reduce inflammation through nucleotide‐binding oligomerization domain 2 (NOD2)/receptor‐interacting protein 2 (RIP2) signaling pathway in rheumatoid arthritis (RA).20, 21. This evidence concerns the gene CD4 and inflammatory bowel disease.